Compare DY & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DY | ARWR |
|---|---|---|
| Founded | 1969 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.3B |
| IPO Year | 1995 | 2009 |
| Metric | DY | ARWR |
|---|---|---|
| Price | $430.22 | $77.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $425.30 | $83.40 |
| AVG Volume (30 Days) | 367.6K | ★ 1.7M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.71 | ★ 99.80 |
| EPS | ★ 9.56 | N/A |
| Revenue | N/A | ★ $16,142,321.00 |
| Revenue This Year | $30.96 | N/A |
| Revenue Next Year | $9.49 | N/A |
| P/E Ratio | $44.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $186.42 | $14.30 |
| 52 Week High | $464.82 | $80.27 |
| Indicator | DY | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 60.92 |
| Support Level | $335.20 | $60.60 |
| Resistance Level | $445.53 | N/A |
| Average True Range (ATR) | 17.44 | 3.90 |
| MACD | 0.66 | 0.03 |
| Stochastic Oscillator | 52.88 | 74.06 |
Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. The company has two reporting segments: Communications and Building Systems. The Communications segment provides specialty contracting services, including program management, planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications and digital infrastructure providers. The Building Systems segment specializes in providing comprehensive building infrastructure solutions, including electrical, energy management, security, and fire safety systems for data centers and other critical facilities. The firm generates key revenue from Communications.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.